ABSTRACT
We report the case of a 21-month-old child suffering from pulmonary fibrosis, who presented with acute respiratory distress and liver damage, due to an accidental overdose of intravenous lipid emulsion. This poisoning is a rare entity, whose potential severity and almost exclusive iatrogenic effect deserve to be remembered.
Subject(s)
Chemical and Drug Induced Liver Injury/etiology , Drug Overdose , Fat Emulsions, Intravenous/adverse effects , Respiratory Insufficiency/chemically induced , Humans , Infant , Male , Medication ErrorsABSTRACT
We study a system of heteronuclear molecules on a triangular lattice and analyze the potential of this system for the experimental realization of a supersolid phase. The ground state phase diagram contains superfluid, solid, and supersolid phases. At finite temperatures and strong interactions there is an additional emulsion region, in contrast with similar models with short-range interactions. We derive the maximal critical temperature T{c} and the corresponding entropy S/N=0.04(1) for supersolidity and find feasible experimental conditions for its realization.
ABSTRACT
BACKGROUND: The antiphospholipid antibody syndrome (AAS), which is characterized by thromboembolic events and/or fetal loss and/or low platelet count associated with antiphospholipid antibodies, may evolve with acute myocardial infarction (AMI). The presence of AAS among young patients with AMI ranges from 14% to 21%, and this condition implies specific therapeutic attitudes as new thrombotic events may occur, according to some authors. MATERIALS AND METHODS: A prospective study was undertaken with 25 patients aged > or = 65 years with AMI that were admitted to our institution during one year who were compared with control patients with similar risk factors. IgG and IgM anticardiolipin antibodies (ACA) were measured in the first 24 hours since the onset of AMI symptoms and three months later. RESULTS: The follow-up ranged from three months to one year. Among patients, ACA positivity in the two measurements was higher (12%) than that observed in the control group (5%) (p = 0.36). ACA positivity on two occasions was not a risk factor for new thrombotic events. CONCLUSION: ACA positivity is higher among AMI patients (measured early and at three months) than among the general population although the presence of such antibodies does not increase the risk for new post-infarction thrombotic events.
Subject(s)
Antiphospholipid Syndrome/complications , Antiphospholipid Syndrome/epidemiology , Myocardial Infarction/etiology , Adult , Age Factors , Aged , Female , Humans , Male , Middle Aged , Prevalence , Prospective StudiesABSTRACT
Introducción. El síndrome antifosfolípido (SAFL), caracterizado por fenómenos trombóticos y/o pérdidas fetales y/o plaquetopenia asociados a anticuerpos antifosfolípidos, puede cursar con infarto agudo de miocardio (IAM). La presencia de SAFL en pacientes jóvenes con IAM oscila entre el 14 por ciento y el 21 por ciento, patología que conlleva actitudes terapéuticas específicas al presentar en su evolución nuevos eventos trombóticos según algunos autores. Material y métodos. Se realiza un estudio prospectivo en 25 pacientes con IAM y edad inferior o igual a 65 años que ingresaron en nuestro centro a lo largo de un año, comparándolos con controles con factores de riesgo similares. Se determinan anticuerpos anticardiolipina (ACA) IgG e IgM en las primeras 24 horas desde el inicio de la clínica de IAM y a los tres meses. Resultados. El seguimiento osciló entre tres meses y un año. En el grupo de pacientes, la positividad de ACA en las dos determinaciones fue superior (12 por ciento) a la del grupo control (5 por ciento) (p = 0,36). La positividad de ACA en dos ocasiones no fue un factor de riesgo para nuevos eventos trombóticos. Conclusión. La positividad de ACA es superior en el grupo de pacientes con IAM (determinados precozmente y a los tres meses) que en la población general, si bien la presencia de dichos anticuerpos no incrementa el riesgo de nuevos eventos trombóticos postinfarto (AU)
